Tag: Breast Cancer

Nipple-sparing mastectomy (NSM) in the setting of breast cancer preserves the nipple-areola complex (NAC) and breast skin envelope. While previous studies have shown that NSM is an acceptable surgical option in select patients with breast cancer, there is limited long-term outcomes data for this approach. In this retrospective cohort...
Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial Preeclampsia is associated with increased morbidity and mortality for both mother and infant. In addition to maternal and fetal assessment, timely delivery after 37 weeks’ gestation is recommended to minimize maternal and perinatal morbidity. In...
Efficacy of prehospital criteria in identifying trauma patients susceptible to undertriage While the early recognition of severe traumatic injury is associated with improved morbidity and mortality, undertriage has been associated with poorer patient outcomes. Previous research has shown that tachypnea and blunt thoracic injury are associated with undertriage. In this...
Hormone therapy is the standard of care for premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor2 (HER2)-negative advanced breast cancer. Ribociclib is an orally administered CDK4/6 inhibitor. Multiple trials have shown that combined ribociclib and endocrine therapy result in significantly improved progression-free survival compared to...
Roxadustat for anemia in patients with kidney disease not receiving dialysis Chronic kidney disease (CKD)-related anemia is associated with significant morbidity, and remains undertreated worldwide. Adequate treatment of CKD-related anemia is associated with reduced transfusion rates and improved clinical outcomes. Roxadustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that...
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of...
Several late-stage cancers have been shown to acquire genomic alterations during disease evolution. In patients with breast cancer, 20% of metastatic tumors develop ESR1 mutations during endocrine therapy. However, the full spectrum of possible genomic alterations in metastatic breast cancer has not been described. In this study, the tumors...
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study Venous thromboembolism (VTE) is a common complication in patients with cancer. Often, VTEs are incidentally detected on imaging studies undertaken for cancer staging or evaluation of treatment response. Current guidelines recommend that...
Breast cancer is the most common cancer seen in females, though it is rare in males. Transgender individuals experience incongruence between the sex assigned to them at birth and their experienced or expressed gender. Within this patient population, there has been an increase in the number of referrals for...
1. Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer patients who have a mutated phosphatidylinositol 3-kinase (PIK3) with the PIK3 inhibitor alpelisib, in addition to fulvestrant, increased progression free survival compared to treatment with fulvestrant alone. 2. The most common severe adverse effects in...